Dyadic International logo
Dyadic International DYAI
$ 0.73 4.09%

Annual report 2025
added 03-25-2026

report update icon

Dyadic International Gross Profit 2011-2026 | DYAI

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Dyadic International

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - 177 K 221 K 268 K 78.2 K 76.7 K 192 K 4.35 M 7.41 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
7.41 M 76.7 K 1.6 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Veracyte Veracyte
VCYT
363 M $ 31.01 -5.46 % $ 2.44 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Aptinyx Aptinyx
APTX
1.56 K - -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
319 K - -6.81 % $ 3.04 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
10.7 K $ 32.67 -4.61 % $ 3.68 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
bluebird bio bluebird bio
BLUE
-4.03 M - - $ 546 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
1.05 K $ 27.39 -2.87 % $ 2.79 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
3.62 B $ 437.99 -3.47 % $ 112 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
7.32 M - - $ 789 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Verastem Verastem
VSTM
14.6 M $ 5.01 -5.29 % $ 347 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
1.34 M $ 0.56 -7.23 % $ 17.3 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
62.8 M $ 12.88 -7.74 % $ 1.95 B usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
519 K $ 38.69 2.35 % $ 152 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
4.67 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
195 M $ 320.49 -2.34 % $ 42 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
64.9 M - - $ 3.74 B usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
37.5 K - - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
Amgen Amgen
AMGN
19 B $ 351.01 -0.61 % $ 189 B usaUSA